MiMedx Revenue 2007-2021 | MDXG

MiMedx revenue from 2007 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
MiMedx Annual Revenue
(Millions of US $)
2020 $248
2019 $299
2018 $359
2017 $321
2016 $222
2015 $187
2014 $118
2013 $59
2012 $27
2011 $8
2010 $1
2009 $0
2009 $
2008 $
2007 $
2007 $
2006 $
MiMedx Quarterly Revenue
(Millions of US $)
2021-06-30 $68
2021-03-31 $60
2020-12-31 $69
2020-09-30 $64
2020-06-30 $54
2020-03-31 $62
2019-12-31 $76
2019-09-30 $89
2019-06-30 $67
2019-03-31 $67
2018-12-31 $93
2018-09-30 $87
2018-06-30 $95
2018-03-31 $84
2017-12-31 $88
2017-09-30 $85
2017-06-30 $76
2017-03-31 $73
2016-12-31 $47
2016-09-30 $64
2016-06-30 $57
2016-03-31 $53
2015-12-31 $52
2015-09-30 $49
2015-06-30 $46
2015-03-31 $41
2014-12-31 $40
2014-09-30 $34
2014-06-30 $26
2014-03-31 $20
2013-12-31 $18
2013-09-30 $16
2013-06-30 $14
2013-03-31 $12
2012-12-31 $11
2012-09-30 $8
2012-06-30 $5
2012-03-31 $4
2011-12-31 $3
2011-09-30 $2
2011-06-30 $2
2011-03-31 $1
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31
2009-09-30
2009-06-30
2009-03-31
2008-12-31
2008-09-30
2008-06-30
2008-03-31
2007-12-31
2007-09-30
2007-06-30
2007-03-31
2006-12-31
2006-09-30
2006-06-30
2006-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.700B $0.248B
MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29